Tag: sunitinib

1. The median follow-up period for health-related quality-of-life (HRQOL) outcomes analyses was 12.9 months 2. For all FKSI-DRS, EORTC QLQ-C30 ...

1. The use of a type I KIT inhibitor, such as PLX9486, in combination with a type II inhibitor, such ...

1. The use of a type I KIT inhibitor, such as PLX9486, in combination with a type II inhibitor, such ...

1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). ...

1. The combination of nivolumab and cabozantinib was superior to sunitinib in untreated advanced renal-cell carcinoma 2. The combination treatment ...

1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). ...

Image: PD  1. Pazopanib and sunitinib showed similar efficacy in treating metastatic renal-cell carcinoma as a first-line therapy.  2. Quality-of-life ...